Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV/AIDS
Pharma
Gilead, Merck phase 3 data back first weekly HIV pill
Detailed phase 3 ISLEND-1 results show zero virologic failures for Gilead and Merck's ISL/LEN as potentially the first weekly HIV pill.
Angus Liu
Jul 21, 2026 10:00am
Gilead's bictegravir, lenacapavir tablet meets mark in phase 3
Nov 13, 2025 9:55am
Gilead campaign urges people living with HIV to 'Choose U'
Sep 4, 2025 11:55am
Gilead's PrEP shows early promise in once-yearly dosing
Mar 11, 2025 2:30pm
GSK’s ViiV plots next steps to fight HIV in Black communities
Feb 7, 2025 1:58pm
Gilead aims to shake up HIV PrEP market with long-acting launch
Aug 9, 2024 11:42am
